Cerebral perfusion imaging is a surrogate marker of Alzheimer’s disease progression in Down syndrome

Takeaway

  • Elevated amyloid burden in people with Down Syndrome is linked to reduced cerebral perfusion.

Why this matters

    Current methods to assess preclinical changes in Alzheimer’s disease in people with Down syndrome can be too burdensome and overwhelming for people with intellectual disabilities and cognitive impairment. These novel findings demonstrate the potential utility of perfusion imaging as a viable, less invasive surrogate marker of Alzheimer’s disease progression in this vulnerable population with Down syndrome.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.